TGA flags compounded Ozempic safety concerns

Pharmacists are being warned that they could be liable for any adverse outcome patients experience should they supply compounded semaglutide-like products  Reports that a telehealth provider plans to make compounded versions of Novo Nordisk’s Ozempic (semaglutide), have prompted the Therapeutic Goods Administration (TGA) to warn that such products “may contain undisclosed and potentially harmful ingredients”. 

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous NT opens door to pharmacist administered NIP shots
Next The top 10: PDL practice alerts